Autor segons l'article: Gabaldó-Barrios, X; Iftimie, S; Hernández-Aguilera, A; Pujol, I; Ballester, F; Fernández, L; Cladellas, S; Castro, A; Joven, J; Camps, J; Simó, JM
Departament: Medicina i Cirurgia Ciències Mèdiques Bàsiques
Autor/s de la URV: Ballester Bastardie, Frederic / Camps Andreu, Jorge / Castro Salomó, Antoni / Iftimie Iftimie, Simona Mihaela / Joven Maried, Jorge / Pujol Bajador, Isabel
Paraules clau: Serology Sars-cov-2 Laboratory automation Diagnostic accuracy Covid-19 Assays Antibodies
Resum: Background Anti-SARS-CoV-2 antibodies have been used in the study of the immune response in infected patients. However, differences in sensitivity and specificity have been reported, depending on the method of analysis. The aim of the present study was to evaluate the diagnostic accuracy of an algorithm in which a high-throughput automated assay for total antibodies was used for screening and two semi-automated IgG-specific methods were used to confirm the results, and also to correlate the analytical results with the clinical data and the time elapsed since infection. Methods We studied 306 patients, some hospitalized and some outpatients, belonging to a population with a high prevalence of COVID-19. One-hundred and ten patients were classified as SARS-CoV-2 negative and 196 as positive by polymerase chain reaction. Results The algorithm and automated assay alone had a specificity and a positive predictive value of 100%, although the sensitivity and negative predictive value of the algorithm was higher. Both methods showed a good sensitivity from day 11 of the onset of symptoms in asymptomatic and symptomatic patients. The absorbance of the total antibodies was significantly higher in severely symptomatic than in asymptomatic or mildly symptomatic patients, which suggests the antibody level was higher. We found 15 patients who did not present seroconversion at 12 days from the onset of symptoms or the first polymerase chain reaction test. Conclusion This study highlights the proper functioning of algorithms in the diagnosis of the immune response to COVID-19, which can help to define testing strategies against this disease.
Àrees temàtiques: Química Medicine (miscellaneous) Medicina i Medical laboratory technology General medicine Farmacia Clinical biochemistry Biochemistry & molecular biology
Accès a la llicència d'ús: https://creativecommons.org/licenses/by/3.0/es/
Adreça de correu electrònic de l'autor: simonamihaela.iftime@urv.cat jorge.camps@urv.cat jorge.joven@urv.cat antoni.castro@urv.cat isabel.pujol@urv.cat frederic.ballester@estudiants.urv.cat
Identificador de l'autor: 0000-0003-0714-8414 0000-0002-3165-3640 0000-0003-2749-4541 0000-0001-5441-6333
Data d'alta del registre: 2024-07-27
Versió de l'article dipositat: info:eu-repo/semantics/publishedVersion
Enllaç font original: https://journals.sagepub.com/action/doSearch?target=default&ContribAuthorStored=Hern%C3%A1ndez-Aguilera%2C+Anna
URL Document de llicència: https://repositori.urv.cat/ca/proteccio-de-dades/
Referència a l'article segons font original: Annals Of Clinical Biochemistry. 58 (6): 614-621
Referència de l'ítem segons les normes APA: Gabaldó-Barrios, X; Iftimie, S; Hernández-Aguilera, A; Pujol, I; Ballester, F; Fernández, L; Cladellas, S; Castro, A; Joven, J; Camps, J; Simó, JM (2021). Clinical performance of the Elecsys (R) anti-SARS-CoV-2 combined in an algorithm with two specific anti-IgG immunoassays for the evaluation of the serological response of patients with COVID-19 in a population with a high prevalence of infection. Annals Of Clinical Biochemistry, 58(6), 614-621. DOI: 10.1177/00045632211038038
DOI de l'article: 10.1177/00045632211038038
Entitat: Universitat Rovira i Virgili
Any de publicació de la revista: 2021
Tipus de publicació: Journal Publications